“Me-Too” Products — Friend or Foe?

Publisher Website
Google Scholar
Abstract
The proliferation of “me-too” drugs leads to beneficial cost reductions, as Lee notes in his Perspective article (Jan. 15 issue),1 but it may also put patients at risk. Each me-too drug comes to the market with limited clinical experience as compared with compounds already in use. Five me-too drugs in the statin and quinolone classes have been withdrawn or restricted because of serious adverse effects that were not recognized until months or years after their approval (temafloxacin, grepafloxacin, cerivastatin, sparfloxacin, and trovafloxacin).

This publication has 2 references indexed in Scilit: